Development and Validation of Novel UPLC-MS/MS Method for the Analysis of Macitentan in Pharmaceutical Formulations

ALBAYRAK M., ATİLA A.

CURRENT PHARMACEUTICAL ANALYSIS, cilt.15, sa.5, ss.554-559, 2019 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 5
  • Basım Tarihi: 2019
  • Doi Numarası: 10.2174/1573412915666190314142531
  • Dergi Adı: CURRENT PHARMACEUTICAL ANALYSIS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.554-559
  • Anahtar Kelimeler: Macitentan, pulmonary arterial hypertension, UPLC-MS/MS, validation, pharmaceutical formulations, specificity, ENDOTHELIN RECEPTOR ANTAGONIST, PHARMACOKINETICS
  • Atatürk Üniversitesi Adresli: Evet

Özet

Introduction: Macitentan is an endothelin receptor antagonist drug used in the treatment of pulmonary arterial hypertension.